GSK and Empirico Inc. announced that they have entered into a worldwide exclusive license agreement for EMP-012, a highly selective first- and potentially best-in-class siRNA, a type of oligonucleotide.
Positive results were announced from its two pivotal phase III trials, B-Well 1 and B-Well 2, evaluating bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis B in over 1,800 patients from 29 countries.
